Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ALX Oncology HoldingsALXO -1.75%27 EV-to-OCF is -2.02 as of Sep. 09, 2026. GuruFocus rates ALXO with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,404 Biotechnology companies, ALX Oncology Holdings ranks worse than 58.62% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ALX Oncology Holdings's Enterprise Value is $143.19 Mil.
ALX Oncology Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-70.78 Mil. Therefore, ALX Oncology Holdings's EV-to-OCF for today is -2.02.
The historical rank and industry rank for ALX Oncology Holdings's EV-to-OCF or its related term are showing as below:
ALXO'
s EV-to-OCF Range Over the Past 10 Years
Min: -86.24 Med: 2.8 Max: 12
Current: -2.02
During the past 8 years, the highest EV-to-OCF of ALX Oncology Holdings was 12.00. The lowest was -86.24. And the median was 2.80.
ALXO's EV-to-OCF is ranked worse than 58.62% of 1404
companies
in the Biotechnology industry
Industry Median: -3.65
vs ALXO: -2.02
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ALX Oncology Holdings's PE Ratio (TTM) for today is calculated as:
ALX Oncology Holdings's share price for today is $1.965.
ALX Oncology Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ALX Oncology Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's EV-to-OCF falls into.
ALX Oncology Holdings's current Enterprise Value is $143.19 Mil.
ALX Oncology Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings (ALXO) has a EV-to-OCF of -2.02 as of Sep. 09, 2026. According to the industry distribution chart, ALX Oncology Holdings ranks #823 out of 1404 companies in the Biotechnology industry, placing it in the top 58.6%.
Is ALX Oncology Holdings' EV-to-OCF too high?
ALX Oncology Holdings' current EV-to-OCF is -2.02. Based on the distribution chart, ALX Oncology Holdings ranks #823 out of 1404 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ALX Oncology Holdings has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does ALX Oncology Holdings' EV-to-OCF compare to AVXL and TRDA?
According to the Biotechnology industry distribution chart, ALX Oncology Holdings ranks #823 out of 1404 companies for EV-to-OCF. This places ALX Oncology Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. ALX Oncology Holdings's current EV-to-OCF is -2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALX Oncology Holdings stock overvalued right now?
ALX Oncology Holdings (ALXO) has a current EV-to-OCF of -2.02. The current EV-to-OCF is -2.02. ALX Oncology Holdings' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ALX Oncology Holdings (ALXO), the current EV-to-OCF is -2.02 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
27GF Score
Get the complete analysis for ALXO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALXO has been successfully added to your 
